Piedmont Healthcare, which uses Glytec‘s insulin therapy tech at three of its hospitals, plans to expand use of the eGlycemic Management System to all of its acute care facilities.
Glytec’s software features evidence-based insulin dosing decision support, surveillance of blood glucose values to identify patients at risk of low and high blood sugar, real-time alerts to warn healthcare workers of an emergency, as well as robust analytics, according to the company.
“Reducing the risks of hyperglycemia and hypoglycemia is extremely important to the health and welfare of our patients,” Dr. N. Spencer Welch, Jr., an endocrinologist at Piedmont Atlanta Hospital, said in prepared remarks. “Blood glucoses outside of the normal range can have a profound impact on patients’ recovery, length of stay, cost of care and readmission rates. Glytec’s software has been very effective in helping us maintain prescribed glucose targets, and as a result, incidence of severe hypoglycemia less than 40 mg/dL – which evidence shows is directly correlated to sentinel events – has been extremely low.”
“Expanding use of eGMS will allow Piedmont Healthcare to adopt best practices across all of its acute care facilities,” Glytec’s CMO Dr. Andrew Rhinehart added. “This translates to less variability, improved patient safety and better outcomes.”
“With eGMS, Piedmont Healthcare will have the means to demonstrate high-reliability care for patients who for reasons of diabetes or stress-induced hyperglycemia require insulin during their stay,” Glytec’s VP of clinical services, Melanie Mabrey, said. “Use of our GlucoMetrics solution will allow us to measure progress and identify areas where improvement may be needed.”
Last month, four new studies were published in the Journal of Diabetes Science and Technology touting patient outcomes linked to Glytec’s eGlycemic diabetes management system.
In both inpatient and outpatient settings, the use of eGMS for insulin therapy management was safer and more effective than traditional standards of care. The studies reported lower rates of hypoglycemia, quicker time to target glucose levels, sustained reductions in A1c levels and faster resolution of diabetic ketoacidosis associated with Glytec’s system.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.